IMUX Analyst Ratings
Immunic, Inc. (IMUX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $93.9M, listed on NASDAQ, employing roughly 100 people, carrying a beta of 1.45 to the broader market. Immunic, Inc. Led by Erik Lundgren, public since 2014-04-17.
Analyst Ratings
In the October 2026 monthly count, 12 analysts rated IMUX: 0 Strong Buy, 12 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 8 analysts, 1 Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $22.13
- Median Target
- $20.50
- High
- $45.00
- Low
- $2.50
- Targets Published, Last 12 Months
- 4
Recent Price Targets
The 4 most recent of 4 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Aug 17, 2026 | Wedbush | Martin Fan | $45.00 | $16.06 |
| May 14, 2026 | Roth Capital | Boobalan Pachaiyappan | $19.00 | $12.54 |
| Apr 30, 2026 | H.C. Wainwright | Matthew Caufield | $22.00 | $10.03 |
| Apr 16, 2026 | Stifel Nicolaus | Not named | $2.50 | $1.00 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 2026 | Wedbush | maintain | Outperform | Outperform |
| Sep 10, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 22, 2026 | B. Riley Securities | maintain | Buy | Buy |
| Apr 30, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 15, 2026 | D. Boral Capital | downgrade | Buy | Hold |
Quantitative Rating
IMUX carries a model grade of C+ (overall score 2 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read IMUX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked IMUX analyst ratings questions
- What is the IMUX consensus price target?
- As of the latest aggregator update, Immunic, Inc. (IMUX) carries a consensus 12-month price target of $22.13. Target ranges run from a low of $2.50 to a high of $45.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on IMUX?
- In the October 2026 monthly count, 12 analysts rated IMUX, and the distribution tilts to the Buy side: 0 Strong Buy, 12 Buy, 0 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has IMUX seen?
- The five most recent ratings actions on IMUX appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect IMUX options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.